Monday, 25 July 2022

NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution

NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution
NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution

Natco Pharma Limitedannounces that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

admin Mon, 07/25/2022 - 17:03

source https://www.pharmatutor.org/pharma-news/2022/natco-announces-approval-of-its-anda-for-cabazitaxel-intravenous-solution

No comments:

Post a Comment

Pharmaceutical Industry and pharma / Life Sciences institute openings 2025

  Intas Pharma Walk in Drive for M.Pharm, B.Pharm | Multiple Posts M.Pharma / B.Pharma. Injectable/Parenteral/Sterile - Aseptic, Manufacturi...